Nothing Special   »   [go: up one dir, main page]

Barrios et al., 2003 - Google Patents

Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients

Barrios et al., 2003

View PDF @Full View
Document ID
5771414209721274450
Author
Barrios A
de Mendoza C
Martín-Carbonero L
Ribera E
Domingo P
Galindo M
Gálvez J
Estrada V
Dalmau D
Asensi V
Soriano V
Publication year
Publication venue
Journal of clinical microbiology

External Links

Snippet

Human immunodeficiency virus (HIV)-infected patients (n= 153) failing antiretroviral therapy after exposure to compounds from all three drug families were monitored for 6 months after beginning a rescue intervention program including tenofovir (TDF). At 3 months, levels of …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G06Q50/24—Patient record management
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires

Similar Documents

Publication Publication Date Title
Sarma et al. Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis
Daar et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Baeten et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
Nichols et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
Markowitz et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo
Hué et al. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals
Borghetti et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication
Von Felden et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection
Weber et al. Uptake of and virological response to antiretroviral therapy among HIV‐infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
Kanters et al. Use of peers to improve adherence to antiretroviral therapy: A global network meta‐analysis
Kirenga et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
Garrigues et al. Identification of tecovirimat resistance-associated mutations in human monkeypox virus-Los Angeles County
Berenstein et al. Adverse events associated with nifurtimox treatment for Chagas disease in children and adults
Levy Caution: should we be treating HIV infection early?
Kim et al. A double-blind, randomized, placebo-controlled, phase II clinical study to evaluate the efficacy and safety of camostat mesylate (DWJ1248) in adult patients with mild to moderate COVID-19
Garcia-Prats et al. Delamanid added to an optimized background regimen in children with multidrug-resistant tuberculosis: results of a phase I/II clinical trial
Roberts et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability, and clinical effect of danirixin in adults with acute, uncomplicated influenza
Kouamou et al. Pretreatment HIV drug resistance among adults initiating or re-initiating first-line antiretroviral therapy in Zimbabwe: fast-tracking the transition to dolutegravir-based first-line regimens?
Inzaule et al. Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk
Paraskevis et al. Molecular tracing of the geographical origin of human immunodeficiency virus type 1 infection and patterns of epidemic spread among migrants who inject drugs in Athens
Chan et al. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV‐1 subtypes: implications for pre‐exposure prophylaxis
Zala et al. Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects
Rokx et al. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV‐1‐infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy
Barrios et al. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients
Mboumba Bouassa et al. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first-and second-line antiretroviral drug regimens recommended by the WHO